Eptastigmine-phosphotriesterase combination in DFP intoxication

Toxicology and Applied Pharmacology

Volumn 140, Issue 2, 1996, Pages 364-369

  Tuovinen, Kai ^a   Kaliste Korhonen, Eila ^a   Raushel, Frank M ^b   Hänninen, Osmo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; DYFLOS; ESTERASE; HEPTYLSTIGMINE TARTRATE; ORGANOPHOSPHATE; PHOSPHOTRIESTERASE; PHYSOSTIGMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; HYDROLYSIS; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MALE; MOUSE; NONHUMAN;

ANIMALIA;

EID: 0030273110     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.0232     Document Type: Article

References (32)

1. Albuquerque, E. X., Deshpande, M. M., Kawabuchi, M., Aracava, Y., Idriss, M., Rickett, D. L., and Boyne, A. F. (1985). Multiple actions of anticholinesterase agents on chemosensitive synapses: Molecular basis for prophylaxis and treatment of organophosphate poisoning. Fundam. Appl. Toxicol. 5, S182-S203.
2. Aracava, Y., Deshpande, S. S., Rickett, D. L., Brossi, A., Schonenberger, B., and Albuquerque, E. X. (1987). The molecular basis of anticholinesterase action on nicotinic and glutamatergic synapses. Ann. N. Y. Acad. Sci. 505, 226-255.
3. Ashani, Y., Shapira, S., Levy, D., Wolfe, A. D., Doctor, B. P., and Raveh, L. (1991). Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem. Pharmacol. 41, 37-41.
4. Augustinsson, K. B., Eriksson, H., and Faijersson, Y. (1978). A new approach to determining cholinesterase activities in samples of whole blood. Clin. Chim. Acta 89, 239-252.
5. Auteri, A., Mosca, A., Lattuada, N., Luzzana, M., Zecca, L., Radice, D., and Imbimbo, B. P. (1993). Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur. J. Clin. Pharmacol. 45, 373-376.
6. Broomfield, C. A. (1992). A purified recombinant organophosphorus acid anhydrase protects mice against soman. Pharmacol. Toxicol. 70, 65-66.
7. Broomfield, C. A., Maxwell, D. M., Solana, R. P., Castro, C. A., Finger, A. V., and Lenz, D. E. (1991). Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J. Pharmacol. Exp. Ther. 259, 633-638.
8. Cazzola, E., Lattuada, N., Zecca, L., Radice, D., Luzzana, M., Imbimbo, B. P., Auteri, A., and Mosca, A. (1993). Rapid potentiometric determination of cholinesterases in plasma and red cells: Application to eptastigmine monitoring. Chem.-Biol. Interact. 87, 265-268.
9. Ellman, G. L., Courtney, K. D., Andres, V., Jr., and Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95.
10. Giacobini, E., Somani, S. M., McIlhany, M., Downen, M., and Hallak, M. (1987). Pharmacokinetics and pharmacodynamics of physostigmine after i.v. administration in beagle dogs. Neuropharmacology 26, 831-836.
11. Hartvig, P., Wiklund, L., and Lindstrom, B. (1986). Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol. Scand. 30, 177-182.
12. Kaliste-Korhonen, E., Ylitalo, P., Hänninen, O., and Raushel, F. M. (1993). Phosphotriesterase decreases paraoxon toxicity in mice. Toxicol. Appl. Pharmacol. 121, 275-278.
13. Lennox, W. J., Harris, L. W., Talbot, B. G., and Anderson, D. R. (1985). Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality. Life Sci. 37, 793-798.
14. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
15. Marta, M., Castellano, C., Oliverio, A., Pavone, F., Pagella, P. G., Brufani, M., and Pomponi, M. (1988). New analogs of physostigmine: Alternative drugs for Alzheimer's disease? Life Sci, 43, 1921-1928.
16. Maxwell, D. M. (1992). The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds. Toxicol. Appl. Pharmacol. 114, 306-312.
17. Maxwell, D. M., and Koplovitz, I. (1990). Effect of endogenous carboxylesterase on HI-6 protection against soman toxicity. J. Pharmacol. Exp. Ther. 254, 440-444.
18. Omburo, G. A., Kuo, J. A., Mullins, L. S., and Raushel, F. M. (1992). Characterization of the zinc binding site of bacterial phosphotriesterase. J. Biol. Chem. 267, 13,278-13,283.
19. Raveh, L., Segall, Y., Leader, H., Rothschild, N., Levanon, D., Henis, Y., and Ashani, Y. (1992). Protection against tabun toxicity in mice by prophylaxis with an enzyme hydrolyzing organophosphate esters. Biochem. Pharmacol. 44, 397-400.
20. Raveh, L., Grunwald, J., Marcus, D., Papier, Y., Cohen, E., and Ashani, Y. (1993). Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. Biochem. Pharmacol. 45, 2465-2474.
21. Somani, S. M., and Khalique, A. (1986). Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration. Fundam. Appl. Toxicol. 6, 327-334.
22. Somani, S. M., and Khalique, A. (1987). Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. Drug. Metab. Dispos. 15, 627-633.
23. Somani, S. M., and Dube, S. N. (1989). Physostigmine - An overview as pretreatment drug for organophosphate intoxication. Int. J. Clin. Pharmacol. Ther. Toxicol. 27, 367-387.
24. Sramek, J. J., Block, G. A., Reines, S. A., Sawin, S. F., Barchowsky, A., and Cutler, N. R. (1995). A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci. 56, 319-326.
25. Tuovinen, K., Kaliste-Korhonen, E., Raushel, F. M., and Hänninen, O. (1994). Phosphotriesterase - A promising candidate for use in detoxification of organophosphates. Fundam. Appl. Toxicol. 23, 578-584.
26. Tuovinen, K., Kaliste-Korhonen, E., Raushel, F. M., and Hänninen, O. (1996). Protection of organophosphate-inactivated esterases with phosphotriesterase. Fundam. Appl. Toxicol. 31, 510-517.
27. Unni, L. K., Hutt, V., Imbimbo, B. P., and Becker, R. E. (1993). Kinetics of cholinesterase inhibition of eptastigmine in man. Eur. J. Clin. Pharmacol. 41, 83-84.
28. Unni, L. K., Radcliffe, J., Latham, G., Sunderland, T., Martinez, R., Potter, W., and Becker, R. E. (1994). Oral administration of heptylphysostigmine in healthy volunteers: A preliminary study. Meth. Find. Exp. Clin. Pharmacol. 16, 373-376.
29. Wolfe, A. D., Rush, R. S., Doctor, B. P., Koplovitz, I., and Jones, D. (1987). Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam. Appl. Toxicol. 9, 266-270.
30. Wolfe, A. D., Maxwell, D. M., Raveh, L., Ashani, Y., and Doctor, B. P. (1991). In vivo detoxification of organophosphate in marmosets by acetylcholinesterase. Proceedings of the 1991 Medical Defense Bioscience Review, pp. 547-550. Edgewood, MD.
31. Wolfe, A. D., Blick, D. W., Murphy, M. R., Miller, S. A., Gentry, M. K., Hartgraves, S. L., and Doctor, B. P. (1992). Use of cholinesterase as pretreatment drugs for the protection of rhesus monkeys against soman toxicity. Toxicol. Appl. Pharmacol. 117, 189-193.
32. Zemaitis, M. A., and Greene, F. E. (1976). Impairment of hepatic microsomal and plasma esterases of the rat by disulfiram and diethyldithiocarbamate. Biochem. Pharmacol. 25, 453-459.